(PR-inside.com) HealthLeaders-InterStudy, a leading provider of managed care market intelligence, reports that the rising costs of oncology drugs are forcing self-insured employers in Arizona, Colorado and Nevada to re-evaluate treatment coverage as a medical benefit. According to the recent West Health Plan Analysis, health insurers in the West have typically kept oncology treatment as a medical benefit, rather than a pharmacy benefit, because the lower costs have ensured that patients complete their course of treatment. However, the report finds that this could change if treatment costs continue to rise. While treatments such as Celgene’s Abraxane, Pfizer’s Epirubicin and tamoxifen citrate are evaluated ..

More...